<DOC>
	<DOCNO>NCT02043756</DOCNO>
	<brief_summary>The purpose study examine toxicity profile , maximum tolerate dose ( MTD ) , pharmacokinetics Mitoxantrone Hydrochloride Liposome Injection .</brief_summary>
	<brief_title>Phase I Pharmacokinetic Study Mitoxantrone Hydrochloride Liposome Injection</brief_title>
	<detailed_description>The trial dose escalation method minimum dose maximum tolerate dose every 3 patient dose group .</detailed_description>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Inclusion criterion : Patients must compliance requirement restriction list consent form Patients Pathology / cytologically proven malignant solid tumor Patients must 1870 year old , male female Failure standard chemotherapy Patients good choice may benefit use anthracyclines Patients must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Objective tumor last chemotherapy , biological therapy experimental interval treatment least 4 week Expected survival time â‰¥ 3 month Patients agree take effective contraceptive measure trial Blood routine , liver kidney function , cardiac function examination accordance follow requirement . Exclusion criterion : Pregnancy breastfeed woman Multiple sclerosis Patients histories ischemic heart disease heart congestive , arrhythmia need treatment significant valvular disease Patients heart disease induce anthracycline Patients require antineoplastic treatment Patients temperature 38 degree active infection may effect clinical test Patients allergic anthracycline liposomal drug Patients allergic egg , egg product , soybean soybean product Patients uncontrolled primary metastatic brain tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Mitoxantrone Hydrochloride Liposome Injection</keyword>
</DOC>